Sustainable low carbon cell-based platform for scale-up production of high-valued materials for personal care and biopharmaceuticals

现代化妆品充满了石油产品和外来植物的成分。HLL正试图通过工程生物学的可持续生产来改变这种状况。该项目的资金将使HLL能够在蒂斯山谷开发大规模的循环生物制造工艺，为该地区到2040年成为世界上第一个净零排放产业集群的雄心做出贡献。这笔资金将使HLL能够实现其目标，成为一家使用来自农业和海洋废物的有机废物作为原料的高价值生物化学品制造商。到2025年，全球美容市场预计将从4830亿美元增长到7840亿美元，近70%的消费者需要量身定制的可持续绿色产品。由于疫苗和药物输送对纳米颗粒的需求，到2028年，医药脂质市场的价值估计将达到1000亿美元，年增长率为7%。我们的目标是在项目完成两年后，在获得在提赛德山谷工业区建立制造工厂的重大投资后，通过使用我们的蜂窝平台和制造过程产生收入。这个项目是开创性的，在这个发展阶段不太可能得到私人投资者的资助。该项目的资金将使TRL从5级提高到7级，使其对私人投资具有吸引力。随着平台的全面开发，该项目将为化妆品/制药行业提供24种新的高价值成分，预计第5年的收入将达到1亿英镑，在蒂斯山谷创造20至30个就业机会，并为英国的美容、个人护理和制药市场提供新的全球供应链。TU和HLL的成果将展示高价值成分的规模化生产，如细胞信号脂肽、基质因子、山酮、生物表面活性剂（枫ecyin、Surfactin）和脂质，这些成分无法通过合成化学在商业上获得。它将向潜在客户和投资者保证，我们可以大规模生产，降低技术流程的风险，并使我们能够与更大的公司合作。为客户测试、配方和评估提供中试材料。这一过程将为全球工业设计、优化和生产新材料创造工艺知识产权。

Modern Cosmetics are full of ingredients from petroleum products and exotic plants. HLL is trying to change that by manufacturing these sustainably through engineering biology. This project funding will allow HLL to develop a scaled-up circular biomanufacturing process in the Tees Valley, contributing to the region's ambition of becoming the world's first Net Zero industrial cluster by 2040\. Funding will enable HLL to realise its goal as a manufacturer of high-value biochemicals using organic waste products coming from agricultural and marine waste as feedstock.The global beauty market is expected to grow from $483bn to $784bn by 2025, with nearly 70% of consumers demanding tailored and sustainable green products. The pharmaceutical lipid market is estimated to have a value of $100bn by 2028, growing at a rate of 7% annually, driven by the need for nanoparticles for vaccine and drug delivery.We aim to generate revenue from using our cellular platform and manufacturing process after securing significant investment to build a manufacturing facility in Teesside valley Industrial Zone, two years after the completion of this project. The project is pioneering and unlikely to be funded by private investors at this stage of development. Funding for this project will move the TRL from 5 to 7, making it attractive for private investment. With a fully developed platform, the project will deliver 24 new high-value ingredients for the cosmetic/pharmaceutical sector produced sustainably with estimated revenue of £100m in year 5, creating between 20 to 30 jobs in Tees valley and empowering a new global supply chain for the beauty, personal care, and pharmaceutical market right here in the UK.Deliverables from TU and HLL will be to demonstrate the scale-up of high-value ingredients such as cell signalling lipopeptides Matrikines, xanthones, biosurfactants (Fengecyin, Surfactin) and lipids which are not commercially obtainable through synthetic chemistry. It will assure potential customers and investors that we can manufacture at scale, de-risking the tech process and enabling us to engage with larger corporations. Provide pilot scale materials for customer testing, formulation, and evaluation. The process will enable the creation of process IP for designing, optimising, and producing novel materials for the global industry.